Prevention of Bone Loss with Risedronate in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial

Documenti analoghi

• Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
  di: Greenspan, Susan L., et al.
  Pubblicazione: (2008)
• The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer
  di: van Londen, G. J., et al.
  Pubblicazione: (2010)
• Effect of Risedronate on Hip Structural Geometry: A 1-Year, Double-Blind Trial in Chemotherapy-Induced Postmenopausal Women
  di: van Londen, G. J., et al.
  Pubblicazione: (2008)
• The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial
  di: van Londen, G. J., et al.
  Pubblicazione: (2009)
• Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study
  di: Koleck, Theresa A., et al.
  Pubblicazione: (2016)